All In Biotech

Drug Trial Radar · NCT07020923

Monthly Dosing of Atacicept in IgAN

A Study Evaluating Monthly (Every 4 Weeks) Dosing of Atacicept in Patients With IgAN

Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

90

Planned (sponsor's estimate)

Start

May 29, 2025

Primary completion

Sep 22, 2026

Study completion Sep 2027

Sponsor

Lead sponsor
Vera Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Jun 13, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 2, open-label, multicenter, randomized study comprising parallel groups of participants receiving weekly and/or monthly doses of atacicept

Conditions

  • IgA Nephropathy (IgAN)
  • Berger Disease

Interventions

  • AtaciceptDrug

    Drug: Atacicept

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evaluate the effect of atacicept on Gd-IgA1 in patients with IgANTime frame: Up to 24 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Vera Therapeutics

    Brisbane, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.